Comorbidities included hypothyroidism (13.0%) and PCOS (5.6%), while 6.8% were on antihypertensive therapy, 9.9% were smokers, 21.6% reported iron supplementation, and 17.3% were receiving GLP-1 receptor agonists. This evidence concerns the gene GLP1R and polycystic ovary syndrome.